Ocugen and Oculis report quarterly financial results

Biotechnology companies Ocugen and Oculis have reported their recent quarterly financial results.

Ocugen reported a second-quarter 2026 net loss of $24.9 million, or $0.07 per share. The company's operating loss of $16.4 million aligned with analyst estimates. Following the issuance of $130 million in convertible notes in May 2026, Ocugen ended the quarter with $100.4 million in cash, which management expects will fund clinical trials and regulatory approvals through fiscal year 2028. The company plans to begin a Phase 3 trial for OCU410 in GA-dAMD during the third quarter.

Oculis reported quarterly earnings with an earnings per share (EPS) of ($0.20), which exceeded the consensus estimate of ($0.48). The company's revenue for the quarter was $0.38 million, surpassing the estimated $0.22 million. Oculis's stock saw an increase during midday trading on Friday, reaching $12.68.